• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤:综述

Malignant Pleural Mesothelioma: A Comprehensive Review.

作者信息

Jain Molly, Crites Morgan Kay, Rich Patricia, Bajantri Bharat

机构信息

Parkview Health, Fort Wayne, IN 46845, USA.

出版信息

J Clin Med. 2024 Sep 30;13(19):5837. doi: 10.3390/jcm13195837.

DOI:10.3390/jcm13195837
PMID:39407894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11476893/
Abstract

Mesotheliomas are hyperplastic tumors that envelop the serosal membranes that safeguard the body's external surfaces. Although certain instances may exhibit indolent characteristics, a significant number of tumors demonstrate rapid progression and a poor prognosis. Mesotheliomas are typically categorized as benign or malignant, with malignant mesothelioma being more frequently linked to asbestos exposure. Malignant pleural mesothelioma (MPM) predominantly impacts males and often emerges in the late 50 s or beyond, characterized by a median age of early 70 s among patients exposed to asbestos lasting from 2 to 4 decades. Respiratory exposure to asbestos particles leads to the development of malignant mesothelioma, characterized by recurrent inflammation, disruption of cell division, activation of proto-oncogenes, and generation of free radicals. In pleural mesothelioma, BAP1, CDKN2A, and NF are the most often mutated genes. Accurate diagnosis and assessment usually require the use of chest computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET). Radiation therapy, immunotherapy, chemotherapy, and surgery are some of the treatment options that are currently available. This systematic review provides a comprehensive analysis of the latest research, biomarkers, evaluation, and management strategies for malignant pleural mesothelioma.

摘要

间皮瘤是一种增生性肿瘤,包裹着保护身体外表面的浆膜。尽管某些病例可能表现出惰性特征,但大量肿瘤显示出快速进展且预后不良。间皮瘤通常分为良性或恶性,恶性间皮瘤更常与接触石棉有关。恶性胸膜间皮瘤(MPM)主要影响男性,通常在50多岁后期或更晚出现,接触石棉持续2至4十年的患者中位年龄在70岁出头。呼吸道接触石棉颗粒会导致恶性间皮瘤的发生,其特征为反复炎症、细胞分裂破坏、原癌基因激活和自由基产生。在胸膜间皮瘤中,BAP1、CDKN2A和NF是最常发生突变的基因。准确的诊断和评估通常需要使用胸部计算机断层扫描(CT)、磁共振成像(MRI)和正电子发射断层扫描(PET)。放射治疗、免疫治疗、化疗和手术是目前可用的一些治疗选择。本系统综述对恶性胸膜间皮瘤的最新研究、生物标志物、评估和管理策略进行了全面分析。

相似文献

1
Malignant Pleural Mesothelioma: A Comprehensive Review.恶性胸膜间皮瘤:综述
J Clin Med. 2024 Sep 30;13(19):5837. doi: 10.3390/jcm13195837.
2
Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.间皮瘤和良性间皮肿瘤:病理和影像学表现的最新进展。
Radiographics. 2023 Mar;43(3):e220128. doi: 10.1148/rg.220128.
3
Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在鉴别恶性间皮瘤与石棉相关良性胸膜疾病中的临床价值:一项观察性初步研究。
J Thorac Oncol. 2009 Dec;4(12):1480-4. doi: 10.1097/JTO.0b013e3181c0a7ff.
4
An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.一个有石棉接触史的家庭,出现多例胸膜恶性间皮瘤,且无易患性BAP1突变的遗传情况。
Cancer Genet. 2015 Oct;208(10):502-7. doi: 10.1016/j.cancergen.2015.07.004. Epub 2015 Jul 30.
5
BAP1 protein is a progression factor in malignant pleural mesothelioma.BAP1 蛋白是恶性胸膜间皮瘤的进展因子。
Pathol Oncol Res. 2014 Jan;20(1):145-51. doi: 10.1007/s12253-013-9677-2. Epub 2013 Aug 22.
6
CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.CDKN2A 拷贝数和 p16 表达与石棉暴露相关的恶性胸膜间皮瘤。
BMC Cancer. 2019 May 28;19(1):507. doi: 10.1186/s12885-019-5652-y.
7
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.恶性腹膜间皮瘤的基因组分析揭示了表观遗传调控基因BAP1、SETD2和DDX3X的复发性改变。
Mod Pathol. 2017 Feb;30(2):246-254. doi: 10.1038/modpathol.2016.188. Epub 2016 Nov 4.
8
[Malignant pleural mesothelioma: diagnosis and treatment].[恶性胸膜间皮瘤:诊断与治疗]
Rev Pneumol Clin. 2013 Feb;69(1):26-35. doi: 10.1016/j.pneumo.2012.12.003. Epub 2013 Jan 14.
9
Clinical diagnosis of malignant pleural mesothelioma.恶性胸膜间皮瘤的临床诊断
J Thorac Dis. 2018 Jan;10(Suppl 2):S253-S261. doi: 10.21037/jtd.2017.10.09.
10
Inactivation of Cooperates with Losses of and to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.Cooper 失活与 和 缺失协同作用驱动条件性小鼠模型中胸膜恶性间皮瘤的发展。
Cancer Res. 2019 Aug 15;79(16):4113-4123. doi: 10.1158/0008-5472.CAN-18-4093. Epub 2019 May 31.

引用本文的文献

1
Mortality from Pleural and Lung Cancer in Railway Maintenance Workers.铁路维修工人的胸膜癌和肺癌死亡率。
Life (Basel). 2025 Jul 21;15(7):1155. doi: 10.3390/life15071155.
2
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.化疗在胸膜恶性肿瘤治疗中的角色演变:当前证据与未来方向
Cancers (Basel). 2025 Jun 25;17(13):2143. doi: 10.3390/cancers17132143.
3
HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.高迁移率族蛋白B1作为恶性间皮瘤的关键介质及石棉相关癌症治疗的潜在靶点
Toxics. 2025 May 28;13(6):448. doi: 10.3390/toxics13060448.
4
Pseudoachalasia Due to Malignant Pleural Mesothelioma Involving the Esophagus.恶性胸膜间皮瘤累及食管导致的假性贲门失弛缓症。
Cureus. 2025 May 15;17(5):e84161. doi: 10.7759/cureus.84161. eCollection 2025 May.
5
BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives.BAP1突变与胸膜间皮瘤:遗传学见解、临床意义及治疗前景
Cancers (Basel). 2025 May 6;17(9):1581. doi: 10.3390/cancers17091581.
6
Advanced imaging techniques and artificial intelligence in pleural diseases: a narrative review.胸膜疾病中的先进成像技术与人工智能:一篇叙述性综述
Eur Respir Rev. 2025 Apr 2;34(176). doi: 10.1183/16000617.0263-2024. Print 2025 Apr.
7
DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.DNA甲基化调控的HLA-C表达调节免疫反应和代谢改变,以影响间皮瘤的预后。
Cancer Immunol Immunother. 2025 Mar 25;74(5):158. doi: 10.1007/s00262-025-04012-4.
8
Prognostic Value of Chest CT Volumetric Analysis in Patients with Malignant Pleural Mesothelioma.胸部CT容积分析在恶性胸膜间皮瘤患者中的预后价值
J Clin Med. 2025 Feb 25;14(5):1547. doi: 10.3390/jcm14051547.
9
Exploring the Anticancer Potential of NO-Donor Oxadiazole Assemblies Against Malignant Pleural Mesothelioma.探索一氧化氮供体型恶二唑组装体对恶性胸膜间皮瘤的抗癌潜力。
Pharmaceutics. 2025 Feb 10;17(2):230. doi: 10.3390/pharmaceutics17020230.

本文引用的文献

1
Further insights into MARS 2.对MARS 2的进一步见解。
Lancet Respir Med. 2024 Sep;12(9):e54. doi: 10.1016/S2213-2600(24)00253-4.
2
Further insights into MARS 2.对MARS 2的进一步见解。
Lancet Respir Med. 2024 Sep;12(9):e52. doi: 10.1016/S2213-2600(24)00251-0.
3
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.广泛胸膜切除术和化疗与单纯化疗治疗胸膜间皮瘤(MARS 2):一项 3 期随机对照试验。
Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
4
Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.恶性胸膜间皮瘤全身治疗中的新兴新靶点
Cancers (Basel). 2024 Mar 22;16(7):1252. doi: 10.3390/cancers16071252.
5
Hyperthermic intrapleural chemotherapy: an update.热灌注胸腔内化疗:最新进展
J Thorac Dis. 2023 Sep 28;15(9):5064-5073. doi: 10.21037/jtd-23-454. Epub 2023 Aug 11.
6
Comparison of video-assisted pleurectomy/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study.电视辅助胸膜切除术/纤维板剥脱术联合胸腔内热化疗与电视辅助胸腔镜滑石粉胸膜固定术治疗恶性胸膜间皮瘤的比较:一项前瞻性研究。
Heliyon. 2023 May 25;9(6):e16685. doi: 10.1016/j.heliyon.2023.e16685. eCollection 2023 Jun.
7
Serum diagnostic markers for malignant pleural mesothelioma: a narrative review.恶性胸膜间皮瘤的血清诊断标志物:一篇叙述性综述。
Transl Cancer Res. 2022 Dec;11(12):4434-4440. doi: 10.21037/tcr-22-2873.
8
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.一线纳武利尤单抗联合伊匹木单抗与化疗治疗不可切除恶性胸膜间皮瘤患者:CheckMate 743研究的3年结果
Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.
9
Malignant pleural mesothelioma: an update.恶性胸膜间皮瘤:最新进展。
J Bras Pneumol. 2021 Dec 13;47(6):e20210129. doi: 10.36416/1806-3756/e20210129. eCollection 2021.
10
Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的流行病学与临床特征
Cancers (Basel). 2021 Aug 20;13(16):4194. doi: 10.3390/cancers13164194.